Decentralized Clinical Trials of Investigational Medicinal Products
This peer-reviewed paper examines why decentralized clinical trials remain rare in drug development and proposes four practical recommendations to overcome regulatory, technical, and patient-centered barriers to wider adoption of digital health technologies.